123580-74-5

Upstream product

• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 23145-88-2 1-[(4-chlorophenyl)methyl]piperazine 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 1289155-11-8 (S)-2-((1-(benzylsulfonyl)pyrrolidin-3-yl)amino)-1-(4-(4-chlorobenzyl)piperazin-1-yl)ethanone 

Relevant academic research and scientific papers

Design, synthesis, in vitro and in vivo evaluation of novel pyrrolizine-based compounds with potential activity as cholinesterase inhibitors and anti-Alzheimer's agents

Novel series of pyrrolizine based compounds (4–6 and 9–11) were designed, synthesized and evaluated as potential anti-Alzheimer agents. Most of the tested compounds showed selectivity to hAChE over hBChE and effectively inhibited self–induced amyloid beta

Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors

Based on the literature-reported compensatory effect of PI3K on Abl inhibition and the improved preclinical effect of drug combination of Abl and PI3K inhibitors, a series of compounds bearing novel scaffold of (S)-3-aminopyrrolidine was identified as Abl and PI3K dual inhibitors through support vector machine screening tool, which were subsequently synthesized and tested. Most compounds demonstrated promising cytoxicity against a CML leukemia cell-line K562 and moderate inhibition against Abl and PI3K kinases. These compounds induced no apoptosis in K562 cell-line, suggesting that their cytotoxic activities are unlikely duo to other known anti-CML mechanisms. Molecular docking study further showed that the compound 5k could bind with both Abl and PI3K, but the weaker binding with Abl compared to Imatinib is consistent with its low kinase inhibitory rates. These plus literature-reported evidences suggest that the promising cytotoxic effect of our novel compounds might be due to the collective effect of Abl and PI3K inhibition.

Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists

Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCR1 antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model.

Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 1: Identification and structure-activity relationships

Optimization of the lead compound 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2,3-dihydro-indol-1-yl)-ethanone 1 by systematic structure-activity relation (SAR) studies lead to two potent compounds 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)- ethanone 2n and 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)- ethanone 7b. Their related synthesis was also reported.

Pyridazinone derivatives with pharmaceutical activity

A 3(2H)-pyridazinone derivative of the formula (I) its salt, a process for its production and a pharmaceutical composition containing it. STR1 wherein each of R1, R2 and R3 which are independent of one another, is a hydrogen atom or a C1-4 alkyl group, X is a chlorine atom or a bromine atom, Y1 is a hydrogen atom, a halogen atom, a nitro group, an amino group or a C1-4 alkoxy group, Y2 is a hydrogen atom, a halogen atom, a hydroxyl group, a C1-4 alkyl group or a C1-4 alkoxy group, A is a C1-5 alkylene chain which may be substituted by a hydroxyl group, B is a carbonyl group or a methylene chain which may be substituted by a C1-4 alkyl group, and each of R4 and R5 which are independent of each other, is a C1-4 alkyl group, or R4 is a hydrogen atom and R5 is --Z--Ar (wherein Z is a C1-5 alkylene chain, and Ar is an aromatic 6-membered ring which may contain a nitrogen atom), or R4 and R5 together form a C2-6 cyclic alkylene group, or R4 and R5 form together with the adjacent nitrogen atom a 4-substituted piperazine ring of the formula: STR2 wherein R6 is a C1-4 alkyl group.